Lithium for bipolar disorder: a review of the recent literature

References

• Licht RW. Lithium: still a major option in the management of bipolar disorder. CNS Neurosci Ther 2012;18(3):219-26
   PubMed Web of Science ®Google Scholar
• Beynon S, Soares-Weiser K, Woolacott N, et al. Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. J Psychopharmacol 2009;23(5):574-91
   PubMedGoogle Scholar
• Muzina DJ, Calabrese JR. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. Aust N Z J Psychiatry 2005;39(8):652-61
   PubMed Web of Science ®Google Scholar
• Moncrieff J. Lithium: evidence reconsidered. Br J Psychiatry 1997;171:113-19
   PubMed Web of Science ®Google Scholar
• Deshauer D, Fergusson D, Duffy A, et al. Re-evaluation of randomized control trials of lithium monotherapy: a cohort effect. Bipolar Disord 2005;7(4):382-7
   PubMedGoogle Scholar
• Blanco C, Laje G, Olfson M, et al. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002;159(6):1005-10
   PubMedGoogle Scholar
• Fenn HH, Robinson D, Luby V, et al. Trends in psychopharmacology of schizoaffective and bipolar affective disorders: a 5-year naturalistic study. Am J Psychiatry 1996;153(5):711-13
   PubMedGoogle Scholar
• Young AH, Hammond JM. Lithium in mood disorders: increasing evidence base, declining use? Br J Psychiatry 2007;191:474-6
   PubMedGoogle Scholar
• Jefferson JW. Old versus new mediations: how much should be taught? Acad Psychiatry 2005;29(2):162-6
   PubMedGoogle Scholar
• Calkin C, Alda M. Beyond the guidelines for bipolar disorder: practical issues in long-term treatment with lithium. Can J Psychiatry 2012;57(7):437-45
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM- IV. 4th edition. American Psychiatric Association; Washington, DC, USA: 1994
   Google Scholar
• WHO. The ICD-10 classification of mental and behavioural disorders. WHO; Geneva, Switzerland: 1992
   Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15(1):1-44
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Kontis D, Gonda X, et al. Treatment of mixed bipolar states. Int J Neuropsychopharmacol 2012;15(7):1015-26
   PubMedGoogle Scholar
• Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011;378(9799):1306-15
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius V, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007;9(6):551-60
   PubMedGoogle Scholar
• Storosum JG, Wohlfarth T, Schene A, et al. Magnitude of effect of lithium in short-term efficacy studies of moderate to severe manic episode. Bipolar Disord 2007;9(8):793-8
   PubMedGoogle Scholar
• Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009;112(1-3):36-49
   PubMed Web of Science ®Google Scholar
• Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66(1):111-21
   PubMed Web of Science ®Google Scholar
• Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 2006;8(1):15-27
   PubMed Web of Science ®Google Scholar
• Bowden CL, Mosolov S, Hranov L, et al. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. Int Clin Psychopharmacol 2010;25(2):60-7
   PubMedGoogle Scholar
• Bowden CL, Göğüş A, Grunze H, et al. A 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorder suffering from a manic episode. Int Clin Psychopharmacol 2008;23(5):254-62
   PubMedGoogle Scholar
• Shafti S, Shahveisi B. Comparison between lithium and valproate in the treatment of acute mania. J Clin Psychopharmacol 2008;28(6):718-20
   PubMedGoogle Scholar
• Niufan G, Tohen M, Quiging A, et al. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J Affect Disord 2008;105(1-3):101-8
   PubMedGoogle Scholar
• Berk M, Ichim L, Book S. Olanzapine compared to lithium in mania: a double-blind randomized, control trial. Int Clin Psychopharmacol 1999;14(6):339-43
   PubMed Web of Science ®Google Scholar
• Shafti SS. Olanzapine vs. lithium in management of acute mania. J Affect Disord 2010;122(3):273-6
   PubMed Web of Science ®Google Scholar
• Li H, Ma C, Wang G, et al. Response and remission rates in Chinese patients with bipolar mania treated for 4 weeks with either quetiapine or lithium: a randomized and double-blind study. Curr Med Res Opin 2008;24(1):1-10
   PubMed Web of Science ®Google Scholar
• Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol: a double-blind randomized controlled trial. Clin Neuropharmacol 1998;21(3):176-80
   PubMed Web of Science ®Google Scholar
• Singh GP. A double-blind comparative study of clinical efficacy of verapamil versus lithium in acute mania. Int J Psychiatr Clin Pract 2008;12(4):303-8
   PubMedGoogle Scholar
• Maj M. The effect of lithium in bipolar disorder: a review of the recent evidence. Bipolar Disord 2003;5:180-8
   PubMedGoogle Scholar
• Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994;271:918-24
   PubMed Web of Science ®Google Scholar
• Malhi GS, Tanious M, Das P, Berk M. The science and practice of lithium therapy. Aust N Z J Psychiatry 2012;46(3):192-211
   PubMed Web of Science ®Google Scholar
• Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. Bipolar Disord 2000;2(3 pt2):261-8
   PubMedGoogle Scholar
• Malhi GS, Tanious M, Gershon S. The lithiumeter: a measured approach. Bipolar Disord 2011;13:219-26
   PubMed Web of Science ®Google Scholar
• Vieta E. Maintenance therapy for bipolar disorder: current and future management options. Expert Rev Neurother 2004;4(6 Suppl 2):S35-42
   Google Scholar
• Van Lieshout RJ, MacQueen GM. Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review. Br J Psychiatry 2010;196(4):266-73
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Grunze H, Panagiotidis P, et al. Treatment of bipolar depression: an update. J Affect Disord 2008;109(1-2):21-34
   PubMed Web of Science ®Google Scholar
• Goodwin GM. Consensus Group of the British Association for Psychopharmacology, 2009. Evidence-based guidelines for treating bipolar disorder: revised second edition- recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23(4):346-88
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). The management of bipolar disorder in adults, children and adolescence, in primary and secondary care – full guideline (National Clinical Practice Guideline number 38). National Institute for Health and Care Excellence; London, UK: 2006
   Google Scholar
• Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64(9):1013-24
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400
   PubMed Web of Science ®Google Scholar
• Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005;162(10):1805-19
   PubMedGoogle Scholar
• Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide and mood disorders: an updated systematic review and meta-analysis. BMJ 2013;346:f3646
   PubMed Web of Science ®Google Scholar
• Oquendo MA, Galfalvy HC, Currier D, et al. Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am J Psychiatry 2011;168(10):1050-6
   PubMedGoogle Scholar
• Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010;71(2):150-62
   PubMed Web of Science ®Google Scholar
• Suppes T, Marangell LB, Bernstein IH, et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord 2008;111(2-3):334-43
   PubMedGoogle Scholar
• Amsterdam JD, Wang CH, Schwarz M, Shults J. Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial. J Affect Disord 2009;112(1-3):219-30
   PubMedGoogle Scholar
• van der Loos ML, Mulder P, Hartong EG, et al. LamLit Study Group. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(2):223-31
   PubMed Web of Science ®Google Scholar
• van der Loos ML, Mulder P, Hartong EG, et al. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr Scand 2010;122(3):246-54
   PubMedGoogle Scholar
• van der Loos ML, Mulder P, Hartong EG, et al. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disord 2011;13(1):111-17
   PubMedGoogle Scholar
• Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158(6):906-12
   PubMed Web of Science ®Google Scholar
• Souza FC, Coodwin CM. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry 1991;158:666-75
   PubMed Web of Science ®Google Scholar
• Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: treatment of bipolar depression. World J Biol Psychiatry 2002;3(3):115-24
   PubMedGoogle Scholar
• Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach. Part I: Clinical efficacy in bipolar disorder. CNS Drugs 2009;23(3):225-40
   PubMed Web of Science ®Google Scholar
• Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004;161(2):217-22
   PubMed Web of Science ®Google Scholar
• Smith L, Cornelius V, Warnock A, et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007;9(4):394-412
   PubMed Web of Science ®Google Scholar
• Weisler RH, Nolen WA, Neijber A, et al. Trial 144 Study Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011;72(11):1452-64
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57:481-9
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005;162(11):2152-61
   PubMed Web of Science ®Google Scholar
• BALANCE investigators and collaborators. Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010;375(9712):385-95
   PubMedGoogle Scholar
• Kessing LV, Hellmund G, Geddes JR, et al. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011;199(1):57-63
   PubMedGoogle Scholar
• Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18 month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65(3):432-41
   PubMed Web of Science ®Google Scholar
• Licht RW, Nielsen JN, Gram LF, et al. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG–6). Bipolar Disord 2010;12(5):483-93
   PubMed Web of Science ®Google Scholar
• Kessing LV, Hellmund G, Andersen PK. An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorder. J Psychopharmacol 2012;26(5):644-52
   PubMedGoogle Scholar
• Hartong EG, Moleman P, Hoogduin CA, LitCar Group. Prophylactic efficacy of lithium versus carbamazepine in treatment-naïve bipolar patients. J CLin Psychiatry 2003;64(2):144-51
   PubMed Web of Science ®Google Scholar
• Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998;18(6):455-60
   PubMedGoogle Scholar
• Greil W, Ludwig-Mayerhofer W, Steller B, et al. The recruitment process for a multicenter study on the long-term prophylactic treatment of affective disorders. J Affect Disord 1993;28(4):257-65
   PubMedGoogle Scholar
• Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders-a randomised study. J Affect Disord 1997;43(2):151-61
   PubMed Web of Science ®Google Scholar
• Greil W, Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 1999;14:283-5
   PubMedGoogle Scholar
• Goodwin FK, Goldstein MA. Optimizing lithium treatment in bipolar disorder: a review of the literature and clinical recommendations. J Psychiatr Pract 2003;9(5):333-43
   PubMedGoogle Scholar
• Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12 month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162(7):1281-90
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II: a randomized, double blind, placebo-substitution study. Am J Psychiatry 2010;167(7):792-800
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Friedman ES, Bowden CL, et al. Lithium Treatment Moderate-Dose Use Study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. Am J Psychiatry 2013;170(1):102-10
   PubMed Web of Science ®Google Scholar
• Carlson GA. In whom does lithium work? Am J Psychiatry 2013;170(5):559
   PubMedGoogle Scholar
• Post RM, Altshuler LL, Frye MA, et al. Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry 2010;71(9):1176-86
   PubMedGoogle Scholar
• Vieta E, Gunther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmaol 2011;14(8):1029-49
   PubMed Web of Science ®Google Scholar
• Altamura AC, Mundo E, Dell’Osso B, et al. Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study. J Affect Disord 2008;110(1-2):135-41
   PubMed Web of Science ®Google Scholar
• Maj M. The impact of lithium prophylaxis on the course of bipolar disorder: a review of the research evidence. Bipolar Disord 2000;2:93-101
   PubMed Web of Science ®Google Scholar
• Schou M. Perspectives on lithium treatment of bipolar disorder: action, efficacy, effect on suicidal behavior. Bipolar Disord 1999;1:5-10
   PubMedGoogle Scholar
• Baldessarini RJ, Tondo L, Hennen J, et al. Is lithium still worth using? An update of selected recent research. Harv Rev Psychiatry 2002;10:59-75
   PubMed Web of Science ®Google Scholar
• Burgess S, Geddes J, Hawton K, et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev 2001(3):CD003013
   Google Scholar
• Goodwin FK, Fireman B, Simon GE, et al. Suicide Risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003;290(11):1467-73
   PubMed Web of Science ®Google Scholar
• Müller-Oerlinghausen B, Wolf T, Ahrens B, et al. Mortality during initial and during later lithium treatment. A collaborative study by the International Group for the Study of Lithium-treated Patients. Acta Psychiatr Scand 1994;90(4):295-7
   PubMedGoogle Scholar
• Tondo L, Baldessarini RJ, Hennen J, et al. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998;59(8):405-14
   PubMedGoogle Scholar
• Kovacsics CE, Gottesman II, Gould TD. Lithium’s antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol 2009;49:475-98
   Google Scholar
• Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006;8(5 Pt 2):625-39
   PubMed Web of Science ®Google Scholar
• Gonzalez-Pinto A, Mosquera F, Alsonso M, et al. Suicide risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord 2006;8(5 Pt2):618-24
   PubMedGoogle Scholar
• Angst J, Angst F, Gerber-Werder R. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years’ follow up. Arch Suicide Res 2005;9(3):279-300
   PubMedGoogle Scholar
• Oquendo MA, Stanley B, Ellis SP, Mann JJ. Protection of human subjects in intervention research for suicidal behavior. Am J Psychiatry 2004;161(9):1558-63
   PubMed Web of Science ®Google Scholar
• Huband N, Ferriter M, Nathan R, Jones H. Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst Rev 2010;17(2):CD003499
   Google Scholar
• Marangell LB, Dennehy EB, Wisniewski SR, et al. Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BD. J Clin Psychiatry 2008;69(6):916-22
   PubMedGoogle Scholar
• McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012;379(9817):721-8
   PubMed Web of Science ®Google Scholar
• Price LH, Heninger GR. Lithium in the treatment of mood disorders. N Engl J Med 1994;331(9):591-8
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Tondo L, Hennen J, Viguera AC. Is lithium still worth using? An update of selected recent research. Harv Rev Psychiatry 2002;10(2):59-75
   PubMedGoogle Scholar
• Albert U, De Cori D, Aguglia A, et al. Lithium-associated hyperparathyroidism and hypercalcaemia: a case-control cross-sectional study. J Affect Disord 2013;151:786-90
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Vieta E, Bouras C, et al. A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic? Int J Neuropsychopharmacol 2008;11(2):269-87
   PubMed Web of Science ®Google Scholar
• Roxanas M, Grace BS, George CR. Renal replacement therapy associated with lithium nephrotoxicity in Australia. Med J Aust 2014;200(4):226-8
   PubMed Web of Science ®Google Scholar
• Bendz H, Schön S, Attman P, Aurell M. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int 2010;77(3):219-24
   PubMed Web of Science ®Google Scholar
• Oliveria JL, Silva Junior GB, Abreu KL, et al. Lithium nephrotoxicity. Rev Assoc Med Bras 2010;56(5):600-6
   PubMedGoogle Scholar
• Presne C, Fakhouri F, Noël LH, et al. Lithium-induced nephropathy: Rate of progression and prognostic factors. Kidney Int 2003;64(2):585-92
   PubMed Web of Science ®Google Scholar
• Gruünfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009;5:270-6
   PubMedGoogle Scholar
• Aiff H, Attman PO, Aurell M, et al. The impact of modern treatment principles may have eliminated lithium-induced renal failure. J Psychopharmacol 2014;28(2):151-4
   PubMedGoogle Scholar
• Carter L, Zolezzi M, Lewczyk A. An updated review of the optimal lithium dosage regimen for renal protection. Can J Psychiatry 2013;58(10):595-600
   PubMedGoogle Scholar
• McIntyre RS, McElroy SL, Eudicone JM, et al. A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder. Prim Care Companion CNS Disord 2011;13(6): pii: PCC.11m01182
   Google Scholar
• Malhi GS, Tanious M. Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations. CNS Drugs 2011;25(4):289-98
   PubMedGoogle Scholar
• Sienaert P, Geeraerts I, Wyckaert S. How to initiate lithium therapy: a systematic review of dose estimation and level prediction methods. J Affect Disord 2013;146(1):15-33
   PubMedGoogle Scholar
• Severus WE, Kleindienst N, Evoniuk G, et al. Is the polarity of relapse/recurrence in bipolar-I disorder patients related to serum lithium levels? Results from an empirical study. J Affect Disord 2009;115(3):466-70
   PubMedGoogle Scholar
• Severus WE, Kleindienst N, Seemüller F, et al. What is the optimal serum lithium level in the long-term treatment of bipolar disorder-a review? Bipolar Disord 2008;10(2):231-7
   PubMed Web of Science ®Google Scholar
• Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48(12):1082-8
   PubMedGoogle Scholar
• Ljubicic D, Letica-Crepulja M, Vitezic D, et al. Lithium treatments: single and multiple daily dosing. Can J Psychiatry 2008;53(5):323-31
   PubMedGoogle Scholar
• Singh LK, Nizamie SH, Akhtar S, Praharaj SK. Improving tolerability of lithium with a once-daily dosing schedule. Am J Ther 2011;18(4):288-91
   PubMed Web of Science ®Google Scholar
• Werneke U, Ott M, Renberg ES, et al. A decision analysis of long-term lithium treatment and risks of renal failure. Acta Psychiatr Scand 2012;126(3):186-97
   PubMedGoogle Scholar
• Biel MG, Peselow E, Mulcare L, et al. Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study. Bipolar Disord 2007;9(5):435-42
   PubMed Web of Science ®Google Scholar
• Gershon S, Chengappa KN, Malhi GS. Lithium specificity in bipolar illness: a classic agent for a classic disorder. Bipolar Disord 2009;11(Suppl 2):34-44
   PubMedGoogle Scholar
• Kleindienst N, Engel R, Greil W. Psychosocial and demographic factors associated with response to prophylactic lithium: a systematic review for bipolar disorders. Psychol Med 2005;35(12):1685-94
   PubMedGoogle Scholar
• Grunze H, Vieta E, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder the World. J Biol Psychiatry 2013;14(3):154-219
   Google Scholar
• Grof P, Duffy A, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry 2002;63(10):942-7
   PubMed Web of Science ®Google Scholar
• Bowden CL, Collins MA, McElroy SL, et al. Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. Neuropsychopharmacology 2005;30(10):1932-9
   PubMedGoogle Scholar
• Kessing LV, Hellmund G, Andersen PK. Predictors of excellent response to lithium: results from a nationwide register-based study. Int Clin Psychopharmacol 2011;26(6):323-8
   PubMedGoogle Scholar
• Cruceanu C, Ambalavanan A, Spegielman D, et al. Family-based exome-based approach identifies rare susceptibility variants for lithium-responsive bipolar disorder. Genome 2013;56:634-40
   PubMedGoogle Scholar
• McCarthy MJ, Leckland S, Kelsoe JR. Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics 2010;11(10):1439-65
   PubMed Web of Science ®Google Scholar
• Rybakowski JK. Response to lithium in bipolar disorder: clinical and genetic findings. ACS Chem Neurosci 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Schulze TG, Alda M, Adli M, et al. The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and the IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology 2010;62:72-8
   PubMedGoogle Scholar
• Perlis RH, Smoller JW, Ferreira MA, et al. A genomewide association study of response to lithium prevention of recurrence in bipolar disorder. Am J Psychiatry 2009;166(6):718-25
   PubMedGoogle Scholar
• Rybakowski JK. Genetics influences on response to mood stabilisers in bipolar disorder: current status of knowledge. CNS Drugs 2013;27(3):165-73
   PubMed Web of Science ®Google Scholar
• Rybakowski JK, Suwalska A, Skibinska M, et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharamcopsychiatry 2005;38:166-70
   PubMedGoogle Scholar
• Dmitrazk-Weglarz M, Rybakowski JK, Suwalska A, et al. Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics 2008;9:1595-603
   PubMedGoogle Scholar
• Chen CH, Lee CS, Lee MT, et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med 2014;370:119-28
   PubMed Web of Science ®Google Scholar
• Manchia M, Adli M, Akula N, et al. Assessment of response to lithium maintenance treatment in bipolar disorder: a Consortium on Lithium Genetics (ConLiGen) report. PLoS One 2013;8(6):e65636
   PubMed Web of Science ®Google Scholar
• Diniz BS, Machado-Verira R, Forlenza OV. Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat 2013;9:493-500
   PubMed Web of Science ®Google Scholar
• Hanstock CC. Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. Int Clin Psychopharmacol 2003;18(2):73-9
   PubMedGoogle Scholar
• Stolk P, Souverein PC, Wilting I, et al. Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot Essent Fatty Acids 2010;82(1):9-14
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93
   PubMed Web of Science ®Google Scholar
• Leeds PR, Yu F, Wang Z, et al. A new avenue for lithium: intervention in traumatic brain injury. ACS Chem Neurosci 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Forlenza OV, De-Paula VJ, Diniz BS. Neuroprotective effects of lithium: implications for the treatment of Alzheimer’s disease and related neurodegenerative disorders. ACS Chem Neurosci 2014. [ Epub ahead of print]
   Google Scholar
• Yildiz A, Vieta E, Leucht S, et al. Efficacy of antimanic treatments: a meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011;36:375-89
   PubMed Web of Science ®Google Scholar
• Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr Scand 1999;100(6):406-17
   PubMedGoogle Scholar